Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
Licensed cannabis operators and ancillary companies are bracing for rising business costs, lost customers and vendor backlash in the wake of President Donald Trump’s erratic blanket tariffs that have rattled the global economy and stoked fears of a recession and accelerated inflation in the United States.
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.AX” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent BioPharma has managed to overcome the wider chaos on the stock markets this week, seeing its stock jump over 40% in the wake of two major announcements.
Tilray’s stock price has tumbled some 24% since the start of the week as its Q3 2025 financial figures failed to meet analysts’ expectations.
The incomprehensible economic strategy of President Trump’s global tariffs has left almost every US industry scratching their heads, and fearing for the future.
‘Liberation day’, set to take place on April 02, has been pitched as the day the Trump administration will roll out sweeping and aggressive tariffs for all of the US’ trading partners.
